Second quarter in brief and the period 1 January – 30 June 2020 Net sales for the period (January to June) amounted to SEK 2,6 million (3,1 million), of which the second quarter contributed SEK 2,6 million (0)....Read More
Fraktalkine pathway mechanism of action for Kancera drug candidate KAND567 is linked to reduced risk of serious complications in COVID-19
Preparation for a clinical study with KAND567 in COVID-19 patients now under way Kancera AB (Nasdaq First North Premier Growth Market: KAN) today announces that independent researchers have published results showing that the fraktalkine system is activated in Covid-19...Read More
Kancera’s drug candidate KAND567 has a positive effect on mobility in a preclinical model of spinal cord injury
Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that an independent research group has published results showing that the company's drug candidate KAND567 has a protective effect on nerve tissue and its function in a preclinical disease...Read More
Interim report for the first quarter 2020, 1 januari-31 March 2020 Kancera AB (publ.), org.nr. 556806-8851.
First quarter in brief 1 January – 31 March 2020 Net sales for the period (January to March) amounted to SEK 0,04 million (3,1). R&D costs for the period amounted to SEK 9,7 million (10,2). Operating profit for the...Read More
This is a translation of a press release in Swedish dated 2020-05-13 Kancera today announces that the company has submitted an application to the Swedish Medicines Agency for permission to conduct a phase II clinical study of the drug...Read More
Kancera AB (Nasdaq First North Premier Growth Market: KAN) today provides an update on the development of the drug candidate KAND145. Results from the ongoing patenting process underscores the level of innovation of KAND145. In addition, positive clinical results...Read More
Kancera AB (Nasdaq First North Premier Growth Market: KAN) today announces that results from the Phase Ib program for KAND567 show that the drug candidate is well tolerated by intravenous administration. Kancera will now compile an application for permission...Read More
Interim report for the fourth quarter 2019, 1 January – 31 December 2019 Kancera AB (publ.), org.nr. 556806-8851.
This is a translation of the report in Swedish.Read More
Kancera AB (Nasdaq First North Premier Growth Market: KAN) today announces that it has received approval from the Finnish Medicines Agency Fimea and the Ethics Committee to start the final part of the phase Ib program for KAND567. The...Read More
Kancera reports in-depth analysis of the Phase Ib program with KAND567, showing the desired effect on the human immune system
Kancera AB (Nasdaq First North Growth Market: KAN) reports results from an in-depth immunological analysis of blood samples from healthy subjects in the ongoing Phase Ib program. The analysis shows that KAND567 effectively blocks certain specific immune cells that...Read More